The Calpain 1 Catalytic Subunit pipeline drugs market research report outlays comprehensive information on the Calpain 1 Catalytic Subunit targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Calpain 1 Catalytic Subunit pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Ophthalmology, Central Nervous System, Gastrointestinal, and Infectious Disease which include the indications Ophthalmology, Glaucoma, Alzheimer’s Disease, Pain, Liver Fibrosis, and Coronavirus Disease 2019 (COVID-19) Pneumonia. It also reviews key players involved in Calpain 1 Catalytic Subunit targeted therapeutics development with respective active and dormant or discontinued products.
The Calpain 1 Catalytic Subunit pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 6, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Calpain 1 Catalytic Subunit overview
Calpain 1 catalytic subunit (CAPN1) is a calcium-regulated non-lysosomal thiol-protease that catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction.
For a complete picture of Calpain 1 Catalytic Subunit’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.